전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-4 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved2,047 programs
AntibodyLimited DatastaleMacroGenicsPhase 2

Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose (Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose)

AML · AML

#AML#Antibody#Phase2#monoclonal-antibody#MacroGenics
Trials 1Status Discontinued
AntibodyLimited DatastaleMacroGenicsPhase 2

Flotetuzumab 300 ng/kg/day, continuous infusion, after multi-step lead-in dose (Flotetuzumab 300 ng/kg/day, continuous infusion, after multi-step lead-in dose)

AML · AML

#AML#Antibody#Phase2#monoclonal-antibody#MacroGenics
Trials 1Status Discontinued
AntibodyLimited DatastaleMacroGenicsPhase 2

Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose (Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose)

AML · AML

#AML#Antibody#Phase2#monoclonal-antibody#MacroGenics
Trials 1Status Discontinued
AntibodyLimited DatastaleMacroGenicsPhase 2

Flotetuzumab 500 ng/kg/day, continuous infusion, after multi-step lead-in dose (Flotetuzumab 500 ng/kg/day, continuous infusion, after multi-step lead-in dose)

AML · AML

#AML#Antibody#Phase2#monoclonal-antibody#MacroGenics
Trials 1Status Discontinued
AntibodyLimited DatastaleMacroGenicsPhase 2

Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multi-step lead-in dose (Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multi-step lead-in dose)

AML · AML

#AML#Antibody#Phase2#monoclonal-antibody#MacroGenics
Trials 1Status Discontinued
AntibodyLimited DatastaleMacroGenicsPhase 2

Flotetuzumab 700 ng/kg/day, continuous infusion, after multi-step lead-in dose (Flotetuzumab 700 ng/kg/day, continuous infusion, after multi-step lead-in dose)

AML · AML

#AML#Antibody#Phase2#monoclonal-antibody#MacroGenics
Trials 1Status Discontinued
CGTLimited DatastaleNanjing IASO Biotechnology Co.,…Phase 1

CT103A (Fully human BCMA chimeric antigen receptor autologous T cell injection, Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A))

Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleBenjamin TomlinsonPhase 1

Fully human anti CD19 CAR-T Cell Dose (Fully human anti CD19 CAR-T Cell Dose)

Non Hodgkin Lymphoma; Acute Lymphoblastic Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleThe First Affiliated Hospital o…Phase 1

GB5005 CART (GB5005 CART)

Non-hodgkin Lymphoma; Refractory Lymphoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleChildren's Mercy Hospital Kansa…Phase 1

GD2 CAR modified Tri-virus specific cytotoxic t-cells (GD2 CAR modified Tri-virus specific cytotoxic t-cells)

Neuroblastoma · GD2

#GD2#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleFuda Cancer Hospital, GuangzhouPhase 2

GD2 CAR-T immunotherapy (GD2 CAR-T immunotherapy)

Glioma of Brain; CAR-T Cell Immunotherapy · GD2

#GD2#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Discontinued
CGTLimited DatastaleYake Biotechnology Ltd.Phase 1

GD2-CAR-T cell (GD2-CAR-T cell)

Neuroblastoma · GD2

#GD2#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleBambino Gesù Hospital and Resea…Phase 1

iC9-GD2-CAR T-cells (GD2-CART01, GD2-CART01 (iC9-GD2-CAR T-cells))

Brain Tumor, Pediatric; Medulloblastoma, Childhood · GD2

#GD2#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleSinobioway Cell Therapy Co., Lt…Preclinical

GD2-targeted CAR-T cells (GD2-targeted CAR-T cells)

Relapsed or Refractory Neuroblastoma · FRα

#FR#CGT#Preclinical#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleNationwide Children's HospitalPhase 2

GEM/DOX + TGFBi expanded NK cells (GEM/DOX + TGFBi expanded NK cells)

Pediatric Sarcoma, Refractory; Pediatric Sarcoma, Relapsed · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleBaylor College of MedicinePhase 1

GINAKIT cells + Etanercept (GINAKIT cells + Etanercept)

Neuroblastoma · Neuroblastoma

#Neuroblastoma#Antibody#Phase1#monoclonal-antibody#Baylor
Trials 1Status Recruiting
CGTLimited DatastaleLakefront Biotherapeutics NVPhase 3

GLPG CAR T-cell therapy (GLPG CAR T-cell therapy)

Hematological Malignancies · Hematological Malignancies

#HematologicalMalignancies#CGT#Phase3#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleBaylor College of MedicinePhase 1

GLYCAR T cells (GLYCAR T cells)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Active
AntibodyLimited DatastaleGeneMedicine Co., Ltd.Phase 2

Part C (GM103 and Pembrolizumab, GM103 and Pembrolizumab (Part C))

Head and Neck Cancer; Malignant Melanoma · Head and Neck Cancer

#HeadandNeckCancer#Antibody#Phase2#monoclonal-antibody#MalignantMelanoma+1
Trials 1Status Recruiting
AntibodyLimited DatastaleCancer Insight, LLCPhase 1

trastuzumab (Herceptin, GP2 peptide + GM-CSF vaccine plus trastuzumab)

Breastcancer · Breastcancer

#Breastcancer#Antibody#Phase1#monoclonal-antibody#Cancer
Trials 1Status Active

65 / 103 pages

← PreviousNext →